PPARγ and AKt gene modulation following pregabalin and duloxetine combination for painful diabetic polyneuropathy.

IF 17.7 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-07-01 DOI:10.1080/17581869.2024.2370758

Ashok K Saxena, Nimisha Thanikkal, G. Chilkoti, P. Gondode, Tusha Sharma, B. D. Banerjee

{"title":"PPARγ and AKt gene modulation following pregabalin and duloxetine combination for painful diabetic polyneuropathy.","authors":"Ashok K Saxena, Nimisha Thanikkal, G. Chilkoti, P. Gondode, Tusha Sharma, B. D. Banerjee","doi":"10.1080/17581869.2024.2370758","DOIUrl":null,"url":null,"abstract":"Aim: Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation (PPARγ and Akt) to understand neuropathic pain's molecular basis. Materials & methods: Diabetic patients with DPN were randomized into groups receiving combination therapy or pregabalin alone for 4 weeks. Pain intensity, gene expression and quality of life were assessed. Results: Combination therapy significantly reduced pain, improved quality of life and upregulated PPARγ and Akt genes compared with monotherapy. Conclusion: Pregabalin and duloxetine combination therapy in DPN led to PPARγ mRNA upregulation and negative correlation of Akt gene expression with pain scores. This combination therapy effectively reduced pain and improved quality of life.Clinical Trial Registration: CTRI/2021/02/031068.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":"260 3","pages":"1-9"},"PeriodicalIF":17.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17581869.2024.2370758","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation (PPARγ and Akt) to understand neuropathic pain's molecular basis. Materials & methods: Diabetic patients with DPN were randomized into groups receiving combination therapy or pregabalin alone for 4 weeks. Pain intensity, gene expression and quality of life were assessed. Results: Combination therapy significantly reduced pain, improved quality of life and upregulated PPARγ and Akt genes compared with monotherapy. Conclusion: Pregabalin and duloxetine combination therapy in DPN led to PPARγ mRNA upregulation and negative correlation of Akt gene expression with pain scores. This combination therapy effectively reduced pain and improved quality of life.Clinical Trial Registration: CTRI/2021/02/031068.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

普瑞巴林和度洛西汀联合治疗糖尿病疼痛性多发性神经病变后的 PPARγ 和 AKt 基因调节作用

目的：糖尿病周围神经病变（DPN）会诱发糖尿病患者的慢性神经病理性疼痛。目前普瑞巴林和度洛西汀等治疗方法的疗效有限。本研究评估了普瑞巴林和度洛西汀联合治疗与普瑞巴林单独治疗对缓解 DPN 疼痛的效果，并探讨了基因调控（PPARγ 和 Akt），以了解神经病理性疼痛的分子基础。材料与方法：将患有 DPN 的糖尿病患者随机分为接受联合疗法或单用普瑞巴林的两组，疗程均为 4 周。对疼痛强度、基因表达和生活质量进行评估。结果与单一疗法相比，联合疗法能明显减轻疼痛，改善生活质量，并上调 PPARγ 和 Akt 基因。结论普瑞巴林和度洛西汀联合治疗 DPN 可导致 PPARγ mRNA 上调，Akt 基因表达与疼痛评分呈负相关。这种联合疗法可有效减轻疼痛并改善生活质量：临床试验注册：CTRI/2021/02/031068。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.